Non-injection-site necrotic skin lesions complicating postoperative heparin thromboprophylaxis

American Journal of Hematology

Volumn 90, Issue 8, 2015, Pages 747-750

  Tassava, Twylla ^a   Warkentin, Theodore E ^b,c  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; WARFARIN; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ARTICLE; BYPASS SURGERY; CASE REPORT; GASTROCNEMIUS MUSCLE; HEMOGLOBIN BLOOD LEVEL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN TISSUE; ILIAC ARTERY OBSTRUCTION; IMMUNOFLUORESCENCE TEST; LEG SWELLING; LEG THROMBOSIS; LEUKOCYTE COUNT; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; PULSE WAVE; SKIN BIOPSY; SKIN NECROSIS; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; ANASTOMOSIS; AORTA; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMORAL ARTERY; LEG; PATHOLOGY; POSTOPERATIVE COMPLICATION; RISK FACTOR; SKIN; THROMBOCYTE; THROMBOCYTOPENIA; VASCULARIZATION; VENOUS THROMBOSIS;

AGED; ANASTOMOSIS, SURGICAL; ANTICOAGULANTS; AORTA; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; FEMORAL ARTERY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LEG; MALE; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SKIN; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 84937422038     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24018     Document Type: Article

References (25)

1. Schwarz T, Buschmann L, Beyer J, et al. Therapy of isolated calf muscle vein thrombosis: A randomized, controlled study. J Vasc Surg 2010; 52:1246-1250.
2. Sales CM, Haq F, Bustami R, Sun F. Management of isolated soleal and gastrocnemius vein thrombosis. J Vasc Surg 2010; 52:1251-1254.
3. Thornsberry LA, SoSicco KI, English JC. The skin and hypercoagulable states. J Am Acad Dermatol 2013; 69:450-462.
4. Wysong A, Venkatesan P. An approach to the patient with retiform purpura. Dermatol Ther 2011; 24:152-172.
5. Crotty R, Nazarian RM, Song PI, Cott EM. Heparin, warfarin, or calciphylaxis? Am J Hematol 2014; 89:785-786.
6. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Haematol 2003; 121:535-555.
7. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other sequelae of the heparin-induced thrombocytopenia syndrome: A nested cohort study. Chest 2005; 127:1857-1861.
8. Schindewolf M, Kroll H, Ackermann H, et al. Heparin-induced non-necrotizing skin lesions: Rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8:1486-1491.
9. Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol 1999; 62:44-48.
10. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127:804-812.
11. Balestra B, Quadri P, Demarmels Biasiutti F, et al. Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites. Eur J Haematol 1994; 53:61-63.
12. Hartman AR, Hood RM, Anagnostopoulos CE. Phenomenon of heparin-induced thrombocytopenia associated with skin necrosis. J Vasc Surg 1988; 7:781-784.
13. Nazliel B, Batur Caglayan HZ, Yildirim Capraz I, et al. Heparin-induced thrombocytopenia leading to stroke, lower extremity arterial occlusive disease, and skin necrosis: A case report. Platelets 2013; 25:129-131.
14. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524.
15. Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient. Hematol Am Soc Hematol Educ Program 2010; 2010:135-143.
16. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: A systemic review and meta-analysis. Blood 2012; 120:4160-4167.
17. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011; 9:105-117.
18. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506.
19. Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2010; 24:755-775.
20. Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: Two distinct but overlapping syndromes. Expert Opin Drug Saf 2009; 8:129-144.
21. Mims MP, Manian P, Rice L. Acute cardiorespiratory collapse from heparin: A consequence of heparin-induced thrombocytopenia. Eur J Haematol 2004; 72:366-369.
22. Popov D, Zarrabi MH, Foda H, Graber M. Pseudopulmonary embolism: Acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis 1997; 29:449-452.
23. Andrews DM, Cubillos SF, Paulino SK, et al. Prospective observational evaluation of the particle immunofiltration anti-platelet factor 4 rapid assay in MICU patients with thrombocytopenia. Crit Care 2013; 17:R143.
24. Warkentin TE, Sheppard JI, Raschke R, Greinacher A. Performance characteristics of a rapid assay for anti-pf4/heparin antibodies, the particle ImmunoFiltration assay. J Thromb Haemost 2007; 5:2308-2310.
25. Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 2005; 25:157-164.